Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risvutatug rezetecan + ivonescimab in advanced solid tumors (Japan, phase 1/2)
jRCT2031260379Phase 2Not yet recruiting
- Sponsor
- GSK
- Start
- Oct 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 2, single-arm trial of risvutatug rezetecan and ivonescimab in Nonhematologic neoplasms, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), sponsored by GSK. Primary endpoints: Safety: Adverse events, serious adverse events, and adverse events of special interest, Safety: Adverse events leading to dose modifications or discontinuations and 8 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
risvutatug rezetecanivonescimab
03
Conditions
Nonhematologic neoplasmssmall cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031260379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260379.